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Background: In addition to its canonical role in musculoskeletal health, several reports have demonstrated that
serum vitamin D level may influence kidney function. However, the effect of pretransplant serum vitamin D level on
subsequent graft function has not been explored. Therefore, this study was undertaken to examine the effect of
serum vitamin D level at the time of kidney transplantation (KT) on subsequent graft function.
Methods: We analyzed 106 patients who underwent KT and for whom 25-hydroxy vitamin D (25-OHD) levels were
measured during hospitalization prior to transplantation. We measured estimated glomerular filtration rates (eGFR)
using the Modification of Diet in Renal Disease (MDRD) formula at baseline and at six-month intervals up to
36 months after KT.
Results: 38.7% of the patients were diagnosed with 25-OHD deficiency defined as less than 10 ng/mL. Recipient
gender (female vs. male, odds ratio [OR] 3.30, 95% CI 1.33-8.21, P= 0.010), serum albumin level (per 1 mg/dl
increase, OR 0.35, 95% CI 0.13-0.98, P= 0.047), and predominant renal replacement therapy modality before KT
(P< 0.001) were found to be independent pretransplant risk factors for 25-OHD deficiency by multivariate logistic
regression analysis. Subsequent repeated measures analysis of covariance revealed that 25-OHD level had the only
significant main effect on eGFR during the 36-month follow-up period [F (1, 88) = 12.07, P= 0.001].
Conclusions: Pretransplant 25-OHD deficiency was significantly associated with a lower post-transplant eGFR,
suggesting that 25-OHD may play an important role in maintaining graft function after KT.Background
25-hydroxy vitamin D (25-OHD) is not only the stored
form of vitamin D in the human body but also the pre-
dominant circulating form of vitamin D in the blood. Due
to its long half-life and high concentration in plasma, the
serum 25-OHD level is considered to be the best measure
of vitamin D status. In addition to its classical role in
maintenance of bone and neuromuscular health, several
reports have demonstrated that poor vitamin D status is
associated with a higher prevalence of hypertension,
chronic heart failure, malignancy [1–3], and increased
mortality not only in patients with chronic kidney disease
not on dialysis, but also in incident hemodialysis patients* Correspondence: khchoi6@yuhs.ac
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reproduction in any medium, provided the orig[4,5]. Moreover, several clinical and experimental studies
have reported a protective role for vitamins D against both
diabetic and non-diabetic renal injuries [6–10].
Patients with kidney failure are at high risk for 25-
OHD deficiency, most likely due to reduced exposure to
sunlight resulting from inactivity and hyperpigmentation
and, to some extent, reduced ingestion of foods that are
natural sources of vitamin D [11]. Even though patients
undergoing kidney transplantation (KT) are generally
healthier than patients with end-stage kidney disease not
eligible for KT, Sadlier et al. reported that only 12% of
patients at the time of KT had a normal 25-OHD con-
centration (> 30 ng/mL), while 29% of patients had 25-
OHD deficiency (< 10 ng/mL) [12]. To date, there has
been little research exploring the consequences of this
high prevalence of vitamin D deficiency at the time of
KT.. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
Figure 1 Study profile. All 106 patients selected from 144 patients
who were screened for 25-OHD level were included in the final
analysis.
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clinical parameters at the time of KT are associated with
vitamin D deficiency and the effect of vitamin D status
prior to KT on subsequent graft function in incident kid-
ney transplant patients.
Methods
Study population
One hundred forty-four patients who had been hospita-
lized for KT at Yonsei University Health System in Seoul,
Korea (latitude: 37.5°N; annual average sunshine hours: 5.8
hours per day) between April 1, 2002 and June 30, 2004
were enrolled and had their 25-OHD level assessed. All
participants were ethnically homogeneous Korean popula-
tion. At enrollment, patients who were less than 16 years
old, had active liver disease or liver cirrhosis, or had
received prior KT were excluded. During follow-up period,
patients who were forced to take vitamin D supplements
after KT for compelling indications, such as pre-existing
uremic osteodystrophy or post-transplant osteoporosis, or
who did not have an equal number of observations (esti-
mated renal function) made at fixed regular intervals were
also excluded from the analysis without imputation of
missing data to minimize estimation bias in statistics used
in this study (details are below) [13]. Therefore, 106 parti-
cipants, who maintained functioning grafts and were regu-
larly assessed for graft function without missing data
throughout the 36-month study period, were only
included in the final analysis (Figure 1).
Baseline demographic and clinical characteristics and la-
boratory data including 25-OHD level were obtained during
hospitalization prior to transplantation. For correcting
serum total calcium for the effects of confounders, such as
protein level or nutritional status, albumin-corrected cal-
cium was calculated as previously described [14]. Predom-
inant renal replacement therapy (RRT) during the
pretransplant end-stage renal disease (ESRD) course was
defined as the RRT modality for >50% of the ESRD period.
Of the screened 144 patients, 16 patients (11.1%)
experienced acute rejection episodes. Diagnosis of all
these rejection episodes was confirmed by biopsy. Of
whom, 11 patients were diagnosed with acute cellular
rejection and were treated with 1 g boluses of intraven-
ous methyl prednisolone for 3 consecutive days or add-
itional polyclonal/monoclonal antibody therapies for
steroid-resistant cases (3 of 11 episodes), which enabled
them to maintain graft patency and be included in the
final analysis. In contrast, 5 patients were diagnosed with
acute mixed humoral/cellular rejection and lost their
grafts despite receiving intensive courses of immunosup-
pressive therapy and returned to dialysis (Figure 1).
These patients were prospectively evaluated for graft
function at six-month intervals for 36 months following
KT by estimated glomerular filtration rate (eGFR) usingthe Modification of Diet in Renal Disease (MDRD) equa-
tion. When analyzing serum 25-OHD concentrations in
this population, 25-OHD deficiency was defined as a
serum 25-OHD< 10 ng/mL because this level is asso-
ciated with an increased risk of rickets in children and
osteomalacia in adults [15]. This study was approved by
the Institutional Review Board of Severance Hospital,
Yonsei University College of Medicine (no. 4-2009-0382)
and written informed consent was obtained from all
subjects.
Measurement of serum 25-OHD level
All specimens measured for 25-OHD were examined in
the endocrinology laboratory at the Medical Research
Center of Yonsei University Health System. 25-OHD
level was evaluated using a Diasorin 25-OHD 125I radio-
immunoassay kit [16], sensitivity ≤ 1.5 ng/mL; inter-assay
coefficient of variation (CV) = 11.7% at 8.6 ng/mL and
8.6% at 33.0 ng/mL.
Immunosuppressive regimens
During the study period, most patients were treated with
a triple regimen of calcineurin inhibitor (cyclosporine or
tacrolimus), purine synthesis inhibitor (azathioprine or
mycophenolate mofetil), and prednisolone.
Statistical analysis
Data analysis was performed using SPSS for Windows,
version 12.0 (SPSS, Chicago, IL, USA). All results are
presented as the mean± standard error of the mean
(SEM). The independent t-test was used to compare
means and analysis of variance (ANOVA) with Bonfer-
roni post-hoc test was used for multiple comparisons
Table 1 Baseline characteristics of the 106 patients
25-OHD (ng/ml) 13.1 ± 0.6
Demographic characteristics
Recipient age (years) 40.2 ± 1.1
Recipient gender (% women) 31 (29.2)
Active vitamin D supplementation before KT 17 (16.0)
Etiology of renal failure (%)
Diabetes mellitus 10 (9.4)
Glomerulonephritis 32 (30.2)
Hypertension and others 64 (60.4)
Duration of dialysis (months) 16.8 ± 2.7
History of cardiovascular disease 8 (7.5)
Smoking 22 (20.8)
Body mass index (kg/m2) 22.8 ± 0.3
Predominant RRT modality before KT (%)
Hemodialysis 49 (46.2)
Peritoneal dialysis 22 (20.8)
Pre-emptive transplantation 35 (33.0)
Transplant type
Living-related donor 76 (71.7)
Living-unrelated donor 29 (27.4)
Deceased donor 1 (0.9)
Donor characteristic
Donor age 35.1 ± 1.0
Donor gender (% women) 46 (43.4)
ABO mismatch (%) 15 (14.2)
Number of HLA mismatches 2.8 ± 0.1
Mismatch at A locus (%) 83 (78.3)
Mismatch at B locus (%) 90 (84.9)
Mismatch at DR locus (%) 87 (82.1)
Laboratory test results
Albumin (g/dl) 3.8 ± 0.0
Calcium (mg/dl) 9.1 ± 0.1
Albumin-corrected calcium (mg/dl) 9.3 ± 0.1
Phosphorus (mg/dl) 5.8 ± 0.2
Alkaline phosphatase (IU/l) 68.6 ± 2.6
Parathyroid hormone (intact; pg/ml) 204.6 ± 19.9
Osteocalcin (ng/ml) 45.2 ± 4.0
Hemoglobin (g/l) 9.5 ± 0.2
Biopsy-proven acute rejection episode 11 (10.4)
Results are expressed as mean± SEM or number (%).
KT, kidney transplantation; RRT, renal replacement therapy.
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pare proportions between variables. Logistic regression
analysis was used to estimate the odds ratios and to
identify the independent pretransplant risk factors for
25-OHD deficiency; all variables at the P< 0.1 level in
univariate analyses and recipient age at KT were
included in the model.
To evaluate the impact of 25-OHD deficiency on
changes in eGFR during the 36 months following KT, a
repeated measures analysis of covariance (ANCOVA)
was conducted with recipient gender, predominant RRT
modality before KT, Biopsy-proven acute rejection epi-
sode, and group according to serum 25-OHD concentra-
tion (25-OHD deficiency vs. control) as between-subjects
factors, the eGFR at each six-month intervals after KT as
a within-subjects factor, and baseline serum albumin
level as a covariate. Because our data violated sphericity
assumptions, multivariate tests using Wilks’ lambda was
used to analyze of the within-subjects effects instead of
univariate tests. All main effects as well as their interac-
tions were entered into the models. If there was a signifi-
cant interaction effect, the Bonferroni correction was
used for post hoc repeated measures ANCOVA. In all
cases, a P-value less than 0.05 was considered significant.
Results
Demographic features
Demographic characteristics of the patients analyzed are
listed in Table 1. The mean age was 40.2 ± 1.1 years
(range: 16.8–60.6 years), and 31 participants (29.2%)
were women. Forty-nine (46.2%) patients had received
hemodialysis, and 22 (20.2%) had received peritoneal dia-
lysis as a predominant RRT modality prior to transplant-
ation. The mean duration of dialysis for these 71 patients
was 16.8 ± 2.7 months. The remaining 35 subjects
(33.0%) received pre-emptive transplants.
Distribution of 25-OHD concentrations
The mean serum 25-OHD concentration was 13.1±0.6 ng/
mL; 41 participants (38.7%) had vitamin D deficiency
defined as less than 10 ng/mL. Considering the latitude of
Korea, it can be assumed that there is a seasonal variation
in ultraviolet exposure, which is a major determinant of 25-
OHD level. Therefore, we analyzed the seasonal variation of
pretransplant 25-OHD levels. As shown in Figure 2, there
was a trend that serum 25-OHD levels were higher in sum-
mer (14.3±0.9 ng/mL)/autumn (14.4±1.4 ng/mL) than in
spring (11.4±0.9 ng/mL)/winter (11.4±1.2 ng/mL), but did
not reach statistical significance both in ANOVA
(P=0.081) and post-hoc multiple comparison using Bonfer-
roni test.
Characteristics of the patients according to serum 25-
OHD level are shown in Table 2. Results showed that
the patients divided into two groups according to 25-OHD level were similar with regard to donor age and
gender, percentage of living and deceased donors, the
number and locus of HLA mismatch, percentage of ABO
mismatch, etiology of renal failure, and duration of dialy-
sis. However, the patients with 25-OHD deficiency at KT
Figure 2 Seasonal variations of pretransplant 25-OHD levels. I
bars represent the standard error. *P-value for the association
between seasons of KT and serum 25-OHD level by analysis of
variance (ANOVA).
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maintenance peritoneal dialysis as a predominant RRT
modality prior to KT (P< 0.001), experienced more fre-
quent biopsy-proven acute rejection episodes (P= 0.003),
and had lower serum levels of hemoglobin (P= 0.028)
and albumin (P< 0.001). Serum calcium level was also
lower in the patients with 25-OHD deficiency
(P= 0.004), but lost significance after correcting for
serum albumin level (P= 0.121).
Among the pretransplant parameters, an adjusted multi-
variate logistic regression model showed that female gender
was independently associated with 25-OHD deficiency
(odds ratio [OR] 3.30, 95% CI 1.33–8.21, P=0.010), and
increased serum albumin level was associated with lower
odds of 25-OHD deficiency (OR 0.35, 95% CI 0.13–0.98,
P=0.047). In addition, predominant RRT modality before
KT was also associated with 25-OHD deficiency (P< 0.001)
(Table 3).Changes in eGFR
A repeated measures ANCOVA was performed to explore
whether pretransplant 25-OHD level had an impact on
changes in eGFR during the 36-month follow-up period as
a main between-subjects factor. We also entered recipient
gender and predominant RRT modality before KT as be-
tween-subjects factors, and serum albumin level as a cov-
ariate into the model because they were potential
pretransplant contributors to differences in 25-OHD level
(Table 3). Since an acute rejection episode is an established
precedent for chronic graft dysfunction [17] and the inci-
dence of posttransplant biopsy-proven acute rejection wassignificantly different according to 25-OHD level (Table 2),
a biopsy-proven acute rejection episode was also included
as a between-subjects factor. The within-subjects factor
was represented by the eGFR at each six-month interval
after KT. Upon multivariate test of within-subjects effect,
there was no significant main effect for eGFR at each 6-
month interval after KT [Wilks’ lambda=0.92, F(6,
83) = 1.39, P=0.228], whereas eGFR at each 6-month
interval after KT by group (25-OHD deficiency vs. control)
interaction was significant [Wilks’ lambda= 0.84, F(6,
83) = 3.56, P=0.003]. This indicates that, while overall
graft function did not change significantly throughout the
36 months after KT, the patterns of changes in graft func-
tion were not consistent and depend on 25-OHD level.
Subsequent analysis of between-subjects effects revealed
that only the main effect of group according to 25-OHD
level (25-OHD deficiency vs. control) was significant, and
none of the interactions associated with group according
to 25-OHD level (25-OHD deficiency vs. control) were sig-
nificant [F(1, 88) = 12.07, P=0.001] (Figure 3) (Table 4).
While the main effect of biopsy-proven acute rejection
episode was not significant, there were significant interac-
tions of Biopsy-proven acute rejection episode with recipi-
ent gender [F(1, 88) = 6.78, P=0.011] and predominant
RRT modality before KT [F(1, 111) = 3.84, P=0.025].
These results suggest that an acute rejection episode
affects post-KT graft function differently according to re-
cipient gender and predominant RRT modality before KT.
Further, post hoc repeated measures ANCOVA analyses
with the Bonferroni corrections revealed that, after an bi-
opsy-proven acute rejection episode, males experienced a
persistently lower level of graft function [F(1, 73) = 7.57,
P=0.007] but females did not [F(1, 29) = 0.65, P=0.426],
and only the graft function of patients receiving pre-emp-
tive KT was affected adversely by a biopsy-proven acute
rejection episode [F(1, 33) = 5.86, P=0.020] but patients
receiving HD [F(1, 47) = 1.80, P=0.185] or PD [F(1,
20) = 0.28, P=0.605] as predominant RRT modality before
KT were not adversely affected.
Discussion
Poor vitamin D status, defined by low level of serum 25-
OHD concentration, has been reported to be associated
with both renal dysfunction and nephrotic syndrome
[18]. In addition, 25-OHD level is positively correlated
with eGFRs [19]. This correlation can in part be
explained by certain conditions that are more prevalent
in the dialysis population, including uremic inflammatory
status, co-morbidities, dark skin color, decreased sun ex-
posure, poor nutritional status, and decreased vitamin D
binding protein.
Our study showed that 38.7% of the analyzed patients
suffered from 25-OHD deficiency, with a mean value of
13.1 ± 0.6 ng/mL. Men had significantly higher levels of
Table 2 Baseline characteristics of patients according to
serum 25-OHD levels
Without 25-OHD
deficiency
(n = 65)
With 25-OHD
deficiency
(n = 41)
P-
values
25-OHD (ng/ml) 16.7 ± 0.6 7.3 ± 0.3 < 0.001
Demographic
characteristics
Recipient age (years) 40.5 ± 1.3 39.9 ± 1.8 0.793
Recipient gender
(% women)
12 (18.5) 19 (46.3) 0.002
Active vitamin D
supplementation before KT
13 (20.0) 4 (9.8) 0.186
Etiology of renal failure (%)
Diabetes mellitus 5 (7.7) 5 (12.2) 0.440
Glomerulonephritis 17 (26.2) 15 (36.6) 0.255
Hypertension and others 43 (66.2) 21 (51.2) 0.126
Duration on dialysis
(months)
19.1 ± 3.7 13.3 ± 3.9 0.309
History of cardiovascular
disease
5 (7.7) 3 (7.3) 0.943
Smoking 15 (23.1) 7 (17.1) 0.458
Body mass index (kg/m2) 23.2 ± 0.4 22.2 ± 0.4 0.102
Predominant RRT modality
before KT (%)
Hemodialysis 42 (64.6) 7 (17.1) < 0.001
Peritoneal dialysis 6 (9.2) 16 (39.0) < 0.001
Pre-emptive transplantation 17 (26.2) 18 (43.9) 0.058
Transplant type
Living-related donor 44 (67.7) 32 (78.0) 0.249
Living-unrelated donor 20 (30.8) 9 (22.0) 0.321
Deceased donor 1 (1.5) 0 (0.0) 1.000
Donor characteristic
Donor age 35.2 ± 1.4 35.0 ± 1.5 0.922
Donor gender (% women) 36 (56.3) 23 (56.1) 0.988
ABO mismatch (%) 12 (18.8) 3 (7.3) 0.153
Number of HLA
mismatches
2.9 ± 0.2 2.8 ± 0.2 0.753
Mismatch at A locus (%) 49 (76.6) 34 (82.9) 0.434
Mismatch at B locus (%) 55 (85.9) 35 (85.4) 0.935
Mismatch at DR locus (%) 52 (81.3) 35 (95.4) 0.585
Biopsy-proven acute
rejection episode
2 (3.1) 9 (22.0) 0.003
Laboratory test results
Albumin (g/dl) 4.0 ± 0.1 3.6 ± 0.1 < 0.001
Calcium (mg/dl) 9.4 ± 0.1 8.7 ± 0.2 0.004
Albumin-corrected
calcium (mg/dl)
9.4 ± 0.1 9.1 ± 0.2 0.121
Phosphorus (mg/dl) 6.0 ± 0.3 5.5 ± 0.2 0.169
Alkaline phosphatase (IU/l) 68.9 ± 3.3 68.0 ± 4.4 0.864
Table 2 Baseline characteristics of patients according to
serum 25-OHD levels (Continued)
Parathyroid hormone
(intact; pg/ml)
205.4 ± 26.9 203.2 ± 29.2 0.957
Osteocalcin (ng/ml) 47.7 ± 5.4 41.2 ± 5.5 0.429
Hemoglobin (g/l) 9.8 ± 0.2 9.0 ± 0.3 0.028
Results are expressed as mean± SEM or number (%).
KT, kidney transplantation; RRT, renal replacement therapy.
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ies conducted in both the general population [20] and in
patients with chronic kidney disease [19]. We also dis-
covered that low serum albumin level was associated
with low 25-OHD level, which might be explained not
only by malnutrition or uremic inflammation but also by
the positive correlation between serum albumin and vita-
min D binding protein levels [21].
Patients with 25-OHD deficiency were more likely to
be receiving peritoneal dialysis than hemodialysis prior
to KT. This can be explained by a substantial loss of vita-
min D binding protein through the peritoneal membrane
[22] or direct loss of 25-OHD via peritoneal membrane
into PD fluid [23], which is unlikely in conventional
hemodialysis due to a general inability to transport mid-
dle-sized proteins.
A principal finding of our prospective study was that
25-OHD level at the time of KT had a substantial effect
on subsequent graft function. Several experimental stud-
ies demonstrated that the active form of vitamin D, 1,25-
dihydroxyvitamin D [1,25-(OH)2D] has a potentially
beneficial effect on the progression of renal disease. Vita-
min D/vitamin D analog therapy has been shown to de-
crease glomerulosclerosis by suppressing the actions of
TGF-β [6], albuminuria, podocyte hypertrophy [8],
mesangial cell proliferation [24], and activation of the
renin-angiotensin system [9]. In addition, other possible
renoprotective roles more specifically related to trans-
plantation have also been noted. There was a tendency
toward fewer acute rejection episodes in 1,25-(OH)2D-
treated kidney transplant cohort [25]. Consistent with
this finding, our study showed that 25-OHD deficiency
was associated with a significantly higher incidence of bi-
opsy-proven acute rejection (P= 0.003, Table 2). Several
other immunomodulatory mechanisms potentially influ-
encing graft function have also been explored, including
attenuation of the activities of CD4+/CD8+ T-cells
[26,27], B-cells [28], and dendritic cells [29] as well as al-
teration of TGFβ-1 and matrix-regulating molecules
[30]. There is little conversion of 25-OHD to 1,25-(OH)
2D due to lack of 1-α hydroxylase in patients with kidney
failure; however, after KT, 1,25-(OH)2D levels can be
restored by allograft [31].
Taken together, these facts imply that a suboptimal
level of 25-OHD, as a substrate for 1,25-(OH)2D, at the
Table 3 Independent predictors for 25-OHD deficiency
using multivariate logistic regression model*
Pretransplant
parameters
B S.E. Wald df P-
values
OR 95% CI
Female sex
vs. male)
1.19 0.47 6.60 1 0.010 3.30 1.33-8.21
Serum albumin
(per 1 mg/dl
increase)
−1.04 0.52 3.96 1 0.047 0.13-0.98
Predominant RRT
modality before KT
13.66 2 < 0.001 0.35
HD (vs. PD) −2.31 0.65 12.64 1 < 0.001 0.10 0.03-0.36
Preemptive KT
(vs. PD)
−0.96 0.60 2.56 1 0.110 0.38 0.12-1.24
*adjusted for recipient age and baseline serum hemoglobin level.
25-OHD, 25-hydroxy vitamin D; RRT, renal replacement therapy; KT, kidney
transplantation; HD, hemodialysis; PD, peritoneal dialysis.
Table 4 Test of between-subject effects on change of
eGFR using repeated measures ANCOVA*
Between-subjects factors df F P-values
Recipient gender 1 3.03 0.085
Predominant RRT modality before KT 2 2.50 0.087
Biopsy-proven acute rejection episode 1 1.83 0.179
25-OHD deficiency 1 12.07 0.001
*Analysis was conducted with all listed between-subjects factors and baseline
serum albumin level as covariate entered into models.
RRT, renal replacement therapy; KT, kidney transplantation; 25-OHD,
25-hydroxy vitamin D.
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graft function from as early as 20 days (Figure 3) to sev-
eral months after KT with its long half-life (up to 25–
30 days) [32]. Additionally, it is well established that
early graft function, under the possible influence of 25-
OHD level at the time of KT, is the most relevant pre-
dictor for long-term graft function [33]. Furthermore, we
cannot completely exclude the possibility that 25-OHD
has another independent role in maintaining graft func-
tion not mediated by 1,25-(OH)2D.
This study had some limitations but also points of rele-
vance. First, serum 25-OHD level was measured only
once at baseline. But, Since posttransplant 25-OHD sup-
plementation is the only proven intervention to change
25-OHD level in renal transplant patients [34], we
excluded all the patients taking post-KT vitamin DFigure 3 Changes in eGFRs between patients with and without 25-OH
after kidney transplantation) to 36 months after kidney transplantatio
subjects effects by repeated measures analysis of covariance (ANCOVA).supplements from the analysis. Therefore, we can cau-
tiously expect that initial differences in 25-OHD might be
maintained during the study period. Second, only serum
25-OHD level was measured, but not 1,25-(OH)2D
level because only serum 25-OHD level is used as a
standard to define vitamin D deficiency. In addition, a
positive correlation between 25-OHD and 1,25-(OH)2D
levels in transplant subjects with mild renal impairment
suggests that the serum level of 25-OHD can be used as
an estimate of 1,25-(OH)2D level [35]. Third, instead of
imputation, we excluded the data of all the patients who
did not have complete details of graft function at fixed
intervals according to protocol. Excluded patients were
those who experienced premature graft failure, were dead,
or had even 1 missing data of graft function at fixed inter-
vals during the study period. This process was required
and helps to minimize the estimation bias in repeated
measures ANCOVA, but meanwhile also might introduce
sample bias since the subjects with complete data may
not be representative of the entire transplant population.
However, more than 90% of the participants, who wereD deficiency from the immediate postoperative period (20 days
n. I bars represent the standard error. *P-value for test of between-
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fixed intervals. Hence, such sample bias is expected to be
relatively small.
Conclusions
In conclusion, we found that 25-OHD deficiency at the
time of KT had a significant adverse effect on graft func-
tion during the first 36 months after KT. Although the
exact mechanism remains to be elucidated, vitamin D
metabolites not only contribute to canonical musculo-
skeletal health but may also play an important role in the
health of other organ systems, including maintenance of
early graft function. Further studies are needed to iden-
tify an effective and safe method for maintaining ad-
equate 25-OHD levels in dialysis patients listed for KT
and to clarify the effect of vitamin D supplementation in
vitamin D deficient KT patients on the post-transplant
outcomes, which is expected to be addressed in the
ongoing randomized controlled trial by Thiem et al.
(ClinicalTrial.gov NCT00752401) [36].
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